Study guide

11.1 Diabetes Mellitus: Glycemic Control, Insulin Therapy & Complications

Singapore Nursing Board SNB

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Legal Framework & Regulatory Governing of Nursing in Singapore

1.1 Nurses and Midwives Act & SNB Regulatory Powers 1.2 Scope of Professional Nursing Practice & Accountability 1.3 Informed Consent, Confidentiality & PDPA in Healthcare

2 Chapter 2: Ethical Standards & Professional Code of Conduct

2.1 SNB Code for Nurses and Midwives & Ethical Principles 2.2 Patient Rights, Advocacy & End-of-Life Ethical Decision-Making 2.3 Safeguarding Vulnerable Patients & Mandatory Reporting

3 Chapter 3: Holistic Patient Assessment & Nursing Process

3.1 Comprehensive Physical Assessment & Vital Signs Monitoring 3.2 Early Warning Scores & Recognising the Deteriorating Patient 3.3 Nursing Diagnosis, Person-Centred Care Planning & Evaluation

4 Chapter 4: Communication, Documentation & Clinical Safety

4.1 Therapeutic Communication & Interpersonal Care Relationships 4.2 Clinical Documentation Standards & ISBAR Clinical Handover 4.3 Clinical Risk Management, Fall Prevention & Patient Safety Goals

5 Chapter 5: Infection Prevention & Control Standards

5.1 Standard & Transmission-Based Precautions (Infection Control) 5.2 Aseptic Technique, Surgical Hand Antisepsis & Wound Care Asepsis 5.3 Outbreak Management, Multi-Drug Resistant Organisms (MDROs) & Bio-waste

6 Chapter 6: Safe Medication Administration & Clinical Pharmacology

6.1 Rights of Medication Administration & High-Alert Medications 6.2 Dosage Calculations, Unit Conversions & Pediatric/Geriatric Adjustments 6.3 Pharmacokinetics, Adverse Drug Reactions & Poison Management 6.4 Medication Reconciliation, Storage & Controlled Substances Act in SG

7 Chapter 7: Intravenous Therapy, Fluid & Electrolyte Management

7.1 Fluid Balance, Electrolyte Disturbances & ABG Interpretation 7.2 Peripheral & Central Venous Line Access, Care & Complications 7.3 Blood Product Transfusion Standards, Safety & Adverse Reaction Management

8 Chapter 8: Respiratory Care & Oxygenation Management

8.1 Airway Management, Oxygen Therapy & Pulse Oximetry 8.2 Tracheostomy Care, Suctioning & Mechanical Ventilation Nursing 8.3 Nursing Care in Acute Respiratory Distress & Chronic Obstructive Pulmonary Disease

9 Chapter 9: Cardiovascular Nursing & Hemodynamic Monitoring

9.1 Cardiac Assessment, ECG Interpretation & Common Arrhythmias 9.2 Acute Coronary Syndrome, Heart Failure & Hypertensive Crises Nursing 9.3 Shock Classification, Fluid Resuscitation & Hemodynamic Monitoring

10 Chapter 10: Medical-Surgical Nursing: Gastrointestinal & Renal Systems

10.1 Enteral & Parenteral Nutrition Management 10.2 Care of Acute Abdomen, Ostomy Care & Gastrointestinal Bleeding 10.3 Acute Kidney Injury, Chronic Kidney Disease & Dialysis Nursing

11 Chapter 11: Endocrine & Metabolic Nursing Management

11.1 Diabetes Mellitus: Glycemic Control, Insulin Therapy & Complications 11.2 Management of Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.3 Thyroid, Adrenal & Pituitary Endocrine Disorders

12 Chapter 12: Neurological Nursing & Musculoskeletal Care

12.1 Neurological Assessment, Glasgow Coma Scale (GCS) & Stroke Care 12.2 Increased Intracranial Pressure (ICP) & Seizure Management 12.3 Musculoskeletal Assessment, Traction, Cast Care & Mobility Promotion

13 Chapter 13: Perioperative & Wound Management

13.1 Preoperative Assessment, Preparation & Informed Consent Verification 13.2 Intraoperative Standards, Surgical Time-Out & Anesthesia Monitoring 13.3 Postoperative Recovery, Pain Management & Wound Healing Staging

14 Chapter 14: Elder Care, Gerontological Nursing & Chronic Disease

14.1 Comprehensive Geriatric Assessment & Frailty Syndromes 14.2 Dementia, Delirium & Depression in Older Adults 14.3 Pressure Injury Prevention, Staging & Advanced Wound Dressings

15 Chapter 15: Mental Health Nursing & Psychosocial Care

15.1 Mental Health Assessment & Therapeutic Nurse-Patient Engagement 15.2 Mood Disorders, Psychosis & Crisis Intervention 15.3 Mental Health Act in Singapore, De-escalation & Patient Safety

16 Chapter 16: Palliative Care & Symptom Management

16.1 Principles of Palliative & End-of-Life Nursing Care 16.2 Pain Assessment, Opioid Titration & Breakthrough Pain Management 16.3 Advance Care Planning (ACP) & Care of the Dying Patient

17 Chapter 17: Interprofessional Collaboration & Care Coordination

17.1 Transdisciplinary Team Dynamics & Multidisciplinary Case Conferences 17.2 Care Coordination, Community Discharge Planning & Continuity of Care 17.3 Conflict Resolution & Interprofessional Communication

18 Chapter 18: Delegation, Supervision & Clinical Leadership

18.1 Principles of Delegation to Enrolled Nurses (ENs) & Ancillary Staff 18.2 Clinical Supervision, Resource Management & Ward Operations 18.3 Quality Improvement, Clinical Audit & Incident Reporting

19 Chapter 19: Evidence-Based Practice, Education & Professional Growth

19.1 Reflective Practice & SNB CPE (Continuing Professional Education) Requirements 19.2 Integrating Evidence-Based Practice (EBP) into Clinical Care 19.3 Clinical Education, Student Preceptorship & Mentorship

11.1 Diabetes Mellitus: Glycemic Control, Insulin Therapy & Complications

Key Takeaways Explain This Topic AI

MOH Clinical Practice Guidelines (CPG) target HbA1c < 7.0% for most non-pregnant adults, with individualized relaxed targets (7.5-8.0%) for frail elderly with severe comorbidities or hypoglycemic unawareness.

Regular (short-acting) and NPH (intermediate-acting) insulins must be mixed standardly by injecting air into cloudy then clear, and drawing clear (Regular) first to prevent contamination of clear vials under SNB High-Alert Medication standards.

The MOH Hypoglycemia Protocol (Rule of 15) for conscious patients with capillary blood glucose < 4.0 mmol/L requires 15g fast-acting oral carbohydrates, rechecking CBG in 15 minutes, and administering complex carbohydrates once normoglycemic.

For unconscious or NPO hypoglycemic patients, administer IV 20% Dextrose 40–50 mL over 1–3 minutes via large peripheral vein or IM/SC Glucagon 1 mg if IV access is unavailable.

Chronic complication surveillance requires annual Singapore Integrated Diabetic Retinopathy Screening (SIDRP), urine albumin-to-creatinine ratio (uACR), eGFR, and 10g monofilament foot testing.

Last updated: July 2026

  • 11.1 Diabetes Mellitus: Glycemic Control, Insulin Therapy & Complications
  • Pathophysiology & Diagnostic Standards in Singapore Practice

Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. In Singapore, diabetes represents a major public health priority under the Ministry of Health (MOH) national "War on Diabetes" initiative. Effective management requires a thorough understanding of disease mechanisms, diagnostic criteria, and strict adherence to nursing safety protocols.

Type 1 Diabetes Mellitus (T1DM) : Characterized by autoimmune destruction of pancreatic beta cells in the Islets of Langerhans, leading to absolute insulin deficiency. Patients require lifelong exogenous insulin replacement and are highly prone to Diabetic Ketoacidosis (DKA).

Type 2 Diabetes Mellitus (T2DM) : Characterized by peripheral insulin resistance combined with a progressive decline in pancreatic beta-cell insulin secretion. T2DM accounts for over 90% of diabetes cases in Singapore and is strongly associated with central obesity, physical inactivity, and metabolic syndrome.

According to the MOH Clinical Practice Guidelines (CPG) on Diabetes Mellitus , diagnostic thresholds using venous plasma samples are defined as follows:

Fasting Plasma Glucose (FPG) : ≥ 7.0 mmol/L \ge 7.0 \text{ mmol/L} ≥ 7.0 mmol/L (following an 8-hour fast).

2-Hour Post-OGTT (Oral Glucose Tolerance Test) : ≥ 11.1 mmol/L \ge 11.1 \text{ mmol/L} ≥ 11.1 mmol/L following a 75g anhydrous glucose load.

Glycated Hemoglobin (HbA1c) : ≥ 6.5 % \ge 6.5\% ≥ 6.5% (48 mmol/mol), measured using a standardized NGSP-certified assay.

Random Plasma Glucose : ≥ 11.1 mmol/L \ge 11.1 \text{ mmol/L} ≥ 11.1 mmol/L in a patient presenting with classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss).

MOH HbA1c Glycemic Targets

Glycemic management must be individualized based on patient age, comorbidities, and hypoglycemia risk:

General Adult Target : HbA1c < 7.0 % \text{HbA1c} < 7.0\% HbA1c < 7.0% to reduce long-term microvascular and macrovascular risk.

Tight Glycemic Target (6.0% – 6.5%) : Younger patients, newly diagnosed T2DM, long life expectancy, and absent micro/macrovascular complications without significant hypoglycemia risk.

Relaxed Target (7.5% – 8.0%) : Frail elderly patients, severe hypoglycemic unawareness, advanced microvascular or macrovascular complications, extensive comorbidities, or limited life expectancy.

Pharmacotherapy & Insulin Management Protocols

Pharmacological intervention in T2DM progresses from oral hypoglycemic agents (OHAs) to combination therapies and injectable agents when glycemic targets are not achieved.

Oral & Non-Insulin Injectable Agents

Drug Class Examples Primary Mechanism Clinical & Nursing Considerations

Biguanides Metformin Decreases hepatic gluconeogenesis; enhances peripheral insulin sensitivity First-line agent. Side effects: GI distress, lactic acidosis (rare). MOH Protocol : Hold 48 hours prior to and after IV iodinated radiocontrast procedures due to acute kidney injury risk.

Sulfonylureas Gliclazide, Glipizide Stimulates pancreatic beta-cell insulin secretion High risk of prolonged hypoglycemia. Avoid Glibenclamide in elderly patients and those with renal impairment ( e G F R < 60 mL/min/1.73m 2 eGFR < 60 \text{ mL/min/1.73m}^2 e GFR < 60 mL/min/1.73m 2 ).

SGLT2 Inhibitors Empagliflozin, Dapagliflozin Inhibits renal tubular glucose reabsorption in PCT Cardioprotective and renoprotective. Risk of mycotic genital infections, volume depletion, and euglycemic DKA . Hold 3 days prior to elective major surgery.

DPP-4 Inhibitors Linagliptin, Sitagliptin Inhibits DPP-4 enzyme, enhancing endogenous GLP-1 levels Weight-neutral, low hypoglycemia risk. Linagliptin requires no dose adjustment in renal impairment.

GLP-1 Receptor Agonists Liraglutide, Dulaglutide, Semaglutide Enhances glucose-dependent insulin secretion, slows gastric emptying Promotes weight loss and cardiovascular risk reduction. Administered SC.

Insulin Types & Action Profiles

Insulin therapy is required in all T1DM patients and T2DM patients failing oral therapy or experiencing severe glycemic decompensation.

Insulin Class Generic / Trade Names Onset Peak Duration Nursing Administration Notes

Rapid-Acting Insulin Lispro (Humalog), Insulin Aspart (Novorapid) 10–15 min 1–2 hours 3–5 hours Administer within 5–15 minutes before or immediately after meals.

Short-Acting Regular Insulin (Actrapid, Humulin R) 30–60 min 2–4 hours 5–8 hours Administer 30 minutes prior to meals. Only insulin suitable for continuous IV infusion.

Intermediate-Acting NPH Insulin (Insulatard, Humulin N) 1–2 hours 4–12 hours 14–24 hours Cloudy suspension; requires gentle rolling (not shaking) 10–20 times before aspiration.

Long-Acting Insulin Glargine (Lantus), Insulin Degludec (Tresiba) 1–2 hours Peakless 24–42 hours Clear solution. Never mix with any other insulin in the same syringe.

Premixed Biphasic Isophane (Mixtard 30/70, Novomix 30) 30 min Dual peaks 18–24 hours Mix of short/rapid and intermediate insulin. Roll thoroughly before administration.

SNB Medication Safety & Administration Technique

High-Alert Medication Safety : Under Singapore Nursing Board (SNB) Medication Administration Standards , subcutaneous and IV insulin are classified as High-Alert Medications. Independent double-checking by two Registered Nurses (RNs) is mandatory for concentration, dose verification, syringe calibration (U-100), and patient identification.

Mixing Insulin Protocol ("Clear before Cloudy") : When combining Regular (short-acting) and NPH (intermediate-acting) insulin in a single syringe:

Inject air into the NPH (cloudy) vial equal to the NPH dose (do not touch liquid).

Inject air into the Regular (clear) vial equal to the Regular dose.

Withdraw the Regular (clear) insulin dose first.

Withdraw the NPH (cloudy) insulin dose second.

Rationale : Prevents contamination of the short-acting clear vial with intermediate-acting cloudy NPH, which would alter the rapid onset profile.

Lipodystrophy Prevention : Rotate injection sites systematically within the same anatomical area (abdomen, thigh, upper arm) at least 1 cm apart. Inject at a 90 ∘ 90^\circ 9 0 ∘ angle ( 45 ∘ 45^\circ 4 5 ∘ for thin individuals). Avoid injecting into hypertrophy or atrophy nodules to ensure consistent absorption.

Acute Hypoglycemia Protocol (MOH Rule of 15)

Hypoglycemia is defined as a Capillary Blood Glucose (CBG) reading of < 4.0 mmol/L < 4.0 \text{ mmol/L} < 4.0 mmol/L (or symptomatic blood glucose drop).

Clinical Manifestations

Autonomic Symptoms (adrenergic/cholinergic response): Tremors, palpitations, diaphoresis, anxiety, hunger, paresthesia.

Neuroglycopenic Symptoms (brain glucose deprivation): Confusion, dizziness, slurred speech, visual disturbances, lethargy, seizures, loss of consciousness.

Singapore Hospital Emergency Rescue Protocol

Conscious & Able to Swallow safely :

Administer 15g fast-acting simple carbohydrate (e.g., 150 mL fruit juice, 3–4 glucose tablets, or 3 teaspoons of sugar dissolved in water).

Rest patient; recheck CBG in 15 minutes ("Rule of 15").

If CBG remains < 4.0 mmol/L < 4.0 \text{ mmol/L} < 4.0 mmol/L , repeat 15g fast-acting carbohydrate. Recheck CBG in 15 min.

Once CBG > 4.0 mmol/L > 4.0 \text{ mmol/L} > 4.0 mmol/L , provide a complex carbohydrate snack (e.g., 2 plain biscuits, slice of bread, or scheduled main meal) to maintain normoglycemia.

Unconscious, Altered Mental State, or NPO :

Secure airway and call for immediate medical assistance / Resuscitation Team.

Establish IV access. Administer IV 20% Dextrose 40–50 mL (or IV 50% Dextrose 20–30 mL) over 1–3 minutes via large peripheral vein (vesicant precaution).

If IV access unavailable: Administer IM or SC Glucagon 1 mg (position patient in lateral recovery position due to risk of emesis upon awakening).

Recheck CBG every 15 minutes until CBG > 4.0 mmol/L > 4.0 \text{ mmol/L} > 4.0 mmol/L and patient recovers consciousness.

Chronic Complications & Preventive Surveillance

Chronic diabetic complications are categorized into microvascular and macrovascular pathology:

Microvascular Complications

Diabetic Retinopathy : Leading cause of blindness in working-age Singaporeans. Requires annual Singapore Integrated Diabetic Retinopathy Screening (SIDRP) fundus photography.

Diabetic Nephropathy : Characterized by persistent microalbuminuria. Screened annually via urine Albumin-to-Creatinine Ratio (uACR; abnormal if > 2.5 mg/mmol > 2.5 \text{ mg/mmol} > 2.5 mg/mmol in men, > 3.5 mg/mmol > 3.5 \text{ mg/mmol} > 3.5 mg/mmol in women) and serum eGFR. Target Blood Pressure per MOH CPG is < 130 / 80 mmHg < 130/80 \text{ mmHg} < 130/80 mmHg , using ACE inhibitors (e.g., Enalapril) or ARBs (e.g., Losartan) for renal protection.

Diabetic Peripheral Neuropathy : Loss of protective sensation assessed using the 10g Semmes-Weinstein Monofilament Test at 10 anatomical sites on each foot.

Comprehensive Diabetic Foot Assessment & Patient Education

Daily Foot Inspection : Inspect soles, heels, and interdigital spaces for calluses, blisters, erythema, or fissures.

Foot Hygiene : Wash feet daily in lukewarm water; dry thoroughly, especially between toes. Apply emollient to dry skin but avoid applying lotion between toes to prevent fungal maceration.

Footwear : Never walk barefoot. Wear custom-fitted, broad-toed supportive shoes with seamless cotton socks.

Nail Care : Cut toenails straight across; file sharp edges. Never cut cuticles or dig into nail corners.

Clinical Nursing Scenario

Scenario : A 64-year-old Malay male with T2DM on twice-daily premixed insulin (Mixtard 30/70, 24 units AM, 12 units PM) is admitted for elective laparoscopic cholecystectomy. At 11:30 AM, while awaiting surgery (NPO status), he becomes diaphoretic, confused, and tachycardic (HR 118 bpm). Bedside CBG measures 2.8 mmol/L 2.8 \text{ mmol/L} 2.8 mmol/L . Action : As the patient is NPO and confused, the nurse immediately secures IV access and administers IV 20% Dextrose 50 mL over 3 minutes as per hospital protocol. The nurse rechecks CBG 15 minutes later (result: 4.6 mmol/L 4.6 \text{ mmol/L} 4.6 mmol/L ), notifies the surgical/endocrine team, documents the incident, and maintains IV 5% Dextrose infusion while NPO.

Loading diagram... Insulin Action Profiles and Mixing Protocol

MOH Glycemic Target Distribution (HbA1c %)